Neurogene Inc. NGNE
28.31
(2.94)
(9.41%)
as of 25 Sep
- Market cap
- $625.4M
- P/E
- 0.0×
Follow NGNE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
18.04 | 16.39 | 12.89 | 10.48 | |
Current Ratio |
18.39 | 16.56 | 13.08 | 10.64 | |
Net Debt/EBITDA |
11.13 | 9.87 | 7.40 | 6.23 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.93 | 0.70 | 0.84 | 0.69 | |
Capex/Depreciation |
3.18 | (0.45) | (0.59) | (0.74) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.92) | (0.82) | (1.17) | (1.05) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.02) | |
Free Cash Flow per Share |
(0.93) | (0.82) | (1.18) | (1.07) | |
Cash per Share |
12.54 | 12.61 | 10.90 | 9.99 | |
Shareholders Equity per Share |
12.54 | 12.42 | 10.66 | 9.63 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.54 | 12.42 | 10.66 | 9.63 | |
Free Cash Flow |
(19.63) | (17.56) | (26.40) | (24.11) | |
Working Capital |
255.81 | 255.36 | 227.88 | 207.41 | |
Capital Expenditures |
(0.13) | (0.13) | (0.28) | (0.35) | |
Net Current Asset Value |
248.23 | 248.05 | 221.39 | 201.68 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Payables |
1.61 | 1.64 | 3.87 | 2.68 | |
Average Assets |
225.98 | 312.17 | 289.22 | 270.84 | |
Average Common Equity |
201.48 | 287.63 | 264.79 | 245.19 |
Columns are period end dates